Broad coverage is better coverage
The first and only Lyme disease vaccine of its kind.Sign in to purchase
The first and only chimeric recombinant canine Lyme disease vaccine. VANGUARD crLyme helps provide broad-spectrum coverage against outer surface protein A (OspA), found in the tick, and contains antigens from multiple types of outer surface protein C (OspC), found in the tick and dog.
Indication: For vaccination of healthy dogs 8 weeks of age or older as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi.
Administration: 1 mL subcutaneous vaccine; dogs should be administered two doses, three weeks apart; annual revaccination recommended.
Why variability of OspC matters
Research has demonstrated that B. burgdorferi can express many different types of OspC in a canine infection.1 One study demonstrated that 11 different types of OspC were present in canine tissue after exposure to B. burgdorferi carrying Ixodes ticks.
B. burgdorferi are obligate bacteria, meaning that they must reside within either an Ixodes spp. tick or another host in order to survive.2 In order to adapt to physiologic differences between hosts and to avoid host immune responses, they frequently change the proteins expressed on their outer surface. OspC expression is required for B. burgdorferi infection of mammalian hosts. While each bacterium can only express one type of OspC on its surface, ticks are generally infected with multiple B. burgfdorferi bacteria.
Until now, a single vaccine which included an OspA protein and a chimeric protein containing antigenic material from seven types of OspC was not possible. At most, previously available vaccines have only contained one type of OspC.Read about the identification of multiple OspCs »
Chimeric recombinant technology
Until now, it was not immunologically feasible to address OspC variability via vaccination
The OspC chimera in VANGUARD crLyme is a single engineered protein that contains antigenic material from seven different types of OspC
Provides targeted immune response to the seven types of OspC
Why both OspA and OspC?
OspA antibodies can help kill B. burgdorferi inside ticks
OspC antibodies can help kill B. burgdoferi inside the tick and dog
Canine Lyme Disease Prevalence 2011–20153
The Centers for Disease Control and Prevention (CDC) noted 28 percent increase in the U.S. human incidence rate between 2005–2013,4 with 30,000 cases reported annually5 while the number of actual cases is projected at 288,000.6
The Companion Animal Parasite Council noted over 201,000 positive canine cases in 2015.3
One in 16 dogs in the United States tests positive for Lyme disease.3
Preventing canine Lyme disease with a vaccine is much easier than treatment. Ninety percent of clinical infections are not seen, and relying solely on parasiticides may not always be enough.4
Rhodes DV, Earnhart CG, Mather TN, Meeus PF, Marconi RT. Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design. Vet J. 2013;198(2):412-418.
Kenedy MR, Lenhart TR, Akins DR. The role of Borrelia burgdorferi outer surface proteins. FEMS Immunol Med Microbiol. 2012;66(1):1-19. doi:10.1111/j.1574-695X.2012.00980.x.
Parasite prevalence maps. Companion Animal Parasite Council. http://www.capcvet.org/parasite-prevalence-maps/. Accessed August 1, 2016.
Lyme disease incidence rates by state, 2005-2014. Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Vector-Borne Diseases (DVBD). http://www.cdc.gov/lyme/stats/chartstables/incidencebystate.html. Accessed August 1, 2016.
Mapping Lyme disease enzootic risk and linking to disease outcomes in the United States. Yale School of Public Health, Department of Epidemiology of Microbial Diseases. http://publichealth.yale.edu/emd/research/zoonosis/projects/tick.aspx. Accessed August 1, 2016.
Hinckley AF, Connally NP, Meek JI, et al. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis. 2014;59(5):676-681. doi:10.1093/cid/ciu397.
All trademarks are the property of Zoetis Services LLC or a related company of a licensor unless otherwise noted.
Zoetis Services LLC. All rights reserved. SAB-00181
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States